EP1228065A1 - [(indol-3-yl)-cycloalkyl]-3-substituierte azetidine zur behandlung von zentralnervensystem-störungen - Google Patents

[(indol-3-yl)-cycloalkyl]-3-substituierte azetidine zur behandlung von zentralnervensystem-störungen

Info

Publication number
EP1228065A1
EP1228065A1 EP00976731A EP00976731A EP1228065A1 EP 1228065 A1 EP1228065 A1 EP 1228065A1 EP 00976731 A EP00976731 A EP 00976731A EP 00976731 A EP00976731 A EP 00976731A EP 1228065 A1 EP1228065 A1 EP 1228065A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
compound
pharmaceutically acceptable
acceptable salt
azetidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00976731A
Other languages
English (en)
French (fr)
Inventor
Magda Asselin
John Watson Ellingboe
Richard Eric Mewshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of EP1228065A1 publication Critical patent/EP1228065A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • This invention relates to new N-(indolyl-cycloalkyl) azetidine derivatives which are useful as pharmaceuticals for the treatment of diseases caused by disorders of the serotonin-affected neurological systems, such as depression and anxiety.
  • compositions which enhance serotonergic neurotransmission are useful for the treatment of many psychiatric disorders, including depression and anxiety.
  • the first generation of non-selective serotonin-affecting drugs operated through a variety of physiological functions which endowed them with several side-effect liabilities.
  • the present invention relates to a new class of molecules which have the ability to act at the 5-HT transporter. Such compounds are therefore potentially useful for the treatment of depression as well as other serotonin disorders.
  • R and R are each independently hydrogen or C, 4 alkyl, or R and R, are linked to form an azetidine ring. These compounds are reported to have activity at the 5HT. receptor and be useful for the treatment of migraine, headache and headache associated with vascular disorder.
  • X is N-R, O, S(O) ra ; m is an integer of 0 to 2; n is an integer of 0 to 4;
  • Ar is an aryl group of 6 to 12 carbon atoms optionally substituted with 1 to 3 groups selected independently from R 3 , R 4 and R s , or a heteroaryl group of 4 to 10 carbon atoms optionally substituted with 1 to 3 selected independently from R 3 , R. and R 5 ;
  • R and R 2 are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, alkoxycarbonyl of 1 to 6 carbon atoms, alkylcarbonyl of 1 to 6 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;
  • R R 3 , R 4 and R 5 are independently H, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, halogen, alkoxy group of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms; and all crystalline forms or a pharmaceutically acceptable salt thereof.
  • X is O, or NR; n is an integer of 0 to 1 ; Ar is an aryl group of 6 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R 3 , R 4 and R 5 , or a heteroaryl group of 5 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R 3 , R, and R 5 ;
  • R and R. are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, or cycloalkyl of 3 to 6 carbon atoms;
  • R,, R 3 , R 4 and R 5 are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, nitrile, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms;
  • X is S(O) m ; m is an integer of 0 to 2; n is an integer of 0 or 1;
  • Ar is an aryl group of 6 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R 3 , R 4 and R 5 , or a heteroaryl group of 5 to 10 carbon atoms optionally substituted with 1 to 3 groups selected independently from R 3 , R 4 and R 5 ;
  • R and R 2 are independently H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, or cycloalkyl of 3 to 6 carbon atoms;
  • R 1? R 3 , R 4 and R 5 are independently selected from H, straight chain alkyl of 1 to 6 carbon atoms, branched alkyl of 3 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, halogen, alkoxy of 1 to 4 carbon atoms, haloalkyl of 1 to 4 carbon atoms, hydroxy, nitro, nitrile, amino, sulfonyl, cyano, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, alkylcarbonyl of 1 to 4 carbon atoms, aminocarbonyl, or alkylaminocarbonyl of 1 to 4 carbon atoms; and all crystalline forms or a pharmaceutically acceptable salt thereof.
  • a subset of these preferred compounds includes those in which X is S(O) m ; m is an integer from 0 to 2; and Ar is a phenyl ring optionally substituted by from 1 to 3 groups independently selected from R 3 , R 4 and R 5 , defined above.
  • Aryl refers to single or multiple 6 to 12 membered aromatic ring radicals including but not limited to phenyl, naphthalene, anthracene, phenanthrene, indene and indacene, in some embodiments of the present invention, the aryl group may be substituted with one to three groups selected from R 3 , R 4 and R,
  • Heteroaryl as used herein refers to single or multiple 5 to 10 membered aromatic ring radicals having from 1 to 3 hetero atoms independently selected from nitrogen, oxygen and sulfur, including, but not limited to, furan, thiophene, pyrrole, imidazole, oxazole, thiazole, isoxazole, pyrazole, isothiazole, oxadiazole, triazole, thiadiazole, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, napthyridine, pteridine, pyridine, pyrazine, pyrimidine, pyridazine, pyran, triazine, indole, isoindole, indazole, indolizine, and isobenzofuran.
  • the heteroaryl group is substituted with one to three groups selected from those of R 3
  • Alkyl whether used alone or as part of another group includes straight and branched chain alkyl groups containing from 1 to 6 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, butyl, /-butyl and t-butyl are encompassed by the term alkyl.
  • alkyl-containing groups herein, such as alkylcarbonyl and alkylaminocarbonyl groups the number of carbon atoms listed refers to the alkyl group, itself, and not including the carbonyl carbon.
  • alkyl may refer to substituted or unsubstituted alkyl.
  • the substituted alkyl groups in these compounds may be fully substituted, such as with perhalogenated compounds.
  • Other alkyl groups in these definitions may be substituted by from 1 to 3 substituents selected from halogen, hydroxy, CN, NO 2 , or NH 3 .
  • the number of carbon number refers to carbon backbone and does not include carbon atoms of substituents such as alkoxy substitutions and the like.
  • Halogen is preferably fluoro, chloro, bromo or iodo.
  • salts are those derived from such organic and inorganic acids as: lactic, citric, acetic, tartaric, succinic, maleic, malonic, oxalic, fumaric, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, and similarly known acceptable acids.
  • R, R., R 2 or R 3 contain a carboxyl group
  • salts of the compounds of this invention may be formed with bases such as alkali metals (Na, K, Li) or the alkaline earth metals (Ca or Mg).
  • the compounds of formula I have been found to have affinity for the 5-HT reuptake transporter. They are therefore useful in the treatment of diseases affected by disorders of the serotonin affected neurological systems, such as depression, anxiety, sleep disorders, sexual dysfunction, alcohol and cocaine addiction, cognition enhancement and related problems.
  • the present invention accordingly provides methods of treatment or prevention of these maladies, the methods comprising administering to a mammal, preferably a human, in need thereof pharmaceutically effective amount of a compound of this invention, or a pharmaceutically acceptable salt thereof.
  • compositions which comprise one or more compounds of this invention, or a pharmaceutically acceptable salt thereof, in combination or association with one or more pharmaceutically acceptable carriers or excipients.
  • the compositions are preferably adapted for oral or subcutaneous administration. However, they may be adapted for other modes of administration.
  • compositions of the invention may be formulated with conventional excipients, such as a filler, a disintegrating agent , a binder, a lubricant, a flavoring agent and the like. They are formulated in conventional manner, for example, in a manner similar to that use for known antihypertensive agents, diuretics and ⁇ - blocking agents.
  • Applicable solid carriers or excipients can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintergrating agents or an encapsulating material.
  • the carrier is a finely divided solid which is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs.
  • the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.
  • suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g.
  • cellulose derivatives preferably sodium carboxymethyl cellulose solution
  • alcohols including monohydric alcohols and polyhydric alcohols e.g. glycols
  • oils e.g. fractionated coconut oil and arachis oil
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.
  • the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • a composition of the invention is in the form of a pharmaceutically effective unit dose.
  • suitable unit dose forms include tablets, capsules and powders in sachets or vials.
  • Such unit dose forms may contain from 0.1 to 100 mg of a compound of the invention and preferably from 2 to 50 mg.
  • Still further preferred unit dosage forms contain 5 to 25 mg of a compound of the present invention.
  • the compounds of the present invention can be administered orally at a dose range of about 0.01 to 100 mg/kg or preferably at a dose range of 0.1 to 10 mg/kg.
  • Such compositions may be administered from 1 to 6 times a day, more usually from 1 to 4 times a day.
  • a compound of formula (2) is reacted with a compound of formula (3) in the presence of a reducing reagent such as sodium triacetoxyborohydride, and acetic acid in a solvent such as dichloroethane at 23 °C to give a compound of formula I in accordance with the procedure described by Abdel-Magid, Carson, Harris, Maryanoff and Shah in J. Org. Chem. 1996, 61, 3849.
  • a reducing reagent such as sodium triacetoxyborohydride
  • acetic acid in a solvent such as dichloroethane at 23 °C
  • a compound of formula (4) is reacted with 1,4-cyclohexanedione monoethylene ketal, potassium hydroxide in methanol at 65 °C to give compounds of formula (5) as described by Wustrow et al. in J. Med. Chem. 1997, 40, 250.
  • Hydrogenation to a compound of formula (6) can be realized by treatment in suitable solvents such as an alcohol, but not limited to ethanol with H, and 5% Pd/C.
  • Hydrolysis to a compound of formula (3) can be carried out using IN HCl in a 1: 1 mixture of THF and water.
  • compounds of formula (2) may be prepared by Scheme III.
  • a compound of formula (7) is prepared by reaction of N-benzhydryl-3- hydroxyazetidine with methanesulfonyl chloride and triethylamine in a solvent such as dichloromethane.
  • Compound (7) is reacted with a compound of formula (9) in the presence of a base such as potassium carbonate in a solvent such as acetonitrile to yield a compound of formula (8).
  • a base such as potassium carbonate
  • a solvent such as acetonitrile
  • Standard N-alkylation methods may be used to convert a compound of formula (9) where R is hydrogen to a compound of formula (9) where R is alkyl.
  • the present invention further provides a compound of the invention for use as an active therapeutic substance.
  • Compounds of formula I are of particular use in the treatment of diseases affected by disorders of the serotonin.
  • the present invention further provides a method of treating depression and anxiety in mammals including man, which comprises administering to the afflicted mammal an effective amount of a compound or a pharmaceutical composition of the invention.
  • the 5-HT transporter affinity of the compounds of this invention was established in accordance with standard pharmaceutically accepted test procedures with representative compounds as follows:
  • the following assay was used to determine a compound's affinity for the 5- HT transporter.
  • a human carcinoma cell line (Jar cells) possessing low endogenous levels of the 5-HT-transporter are seeded into 96 well plates and treated with staurosporine at least 18 h prior to assay. [Staurosporine greatly increases the expression of the 5-HT- transporter.]
  • vehicle, excess of fluoxetine, or test compound is added to various wells on the plate. All wells then receive ⁇ -5-HT and are incubated at 37 °C for 5 min. The wells are then washed with ice cold 50 mM Tris HCl (pH 7.4) buffer and aspirated to remove free 3 H-5-HT.
  • Example 10b 73 4600
  • Example la ⁇ l-[cis-4-(5-Fluoro-lH-indol-3-yl)-cyclohexyl]-azetidin-3-yl)-2-methoxy-phenyl)- amine
  • Step 2 4-(5-Fluoro-lH-3-indoIyl)-cyclohexanone ethylene ketal
  • Step 7 ⁇ l-[cis-4-(5-Fluoro-lH-indol-3-yl)-cyclohexyl]-azetidin-3-yl)-2-methoxy- phenyl)-amine
  • the product was filtered through 150 mL of silica gel using 50% ethyl acetate/hexanes, 75% ethyl acetate/hexanes, and finally 100% ethyl acetate to give 0.150 g of the desired product: mp 158-160 °C.
  • Step 2 4-(5-Cyano-lH-3-indolyl)-cyclohexanone ethylene ketal
  • Example 8b 5-Fluoro-3- ⁇ trans-4-[3-(3-methoxy-phenoxy)-azetidin-l-yl]-cyclohexyl ⁇ -lH- indole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP00976731A 1999-11-08 2000-10-31 [(indol-3-yl)-cycloalkyl]-3-substituierte azetidine zur behandlung von zentralnervensystem-störungen Withdrawn EP1228065A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43611999A 1999-11-08 1999-11-08
US436119 1999-11-08
PCT/US2000/029954 WO2001034598A1 (en) 1999-11-08 2000-10-31 [(indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
EP1228065A1 true EP1228065A1 (de) 2002-08-07

Family

ID=23731187

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00976731A Withdrawn EP1228065A1 (de) 1999-11-08 2000-10-31 [(indol-3-yl)-cycloalkyl]-3-substituierte azetidine zur behandlung von zentralnervensystem-störungen

Country Status (8)

Country Link
EP (1) EP1228065A1 (de)
JP (1) JP2003513970A (de)
CN (1) CN1414962A (de)
AU (1) AU1446601A (de)
BR (1) BR0015401A (de)
CA (1) CA2390531A1 (de)
MX (1) MXPA02004555A (de)
WO (1) WO2001034598A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1638939A2 (de) * 2003-06-24 2006-03-29 Neurosearch A/S Derivative mit aza-ring und deren verwendung als inhibitoren der wiederaufnahme von monoaminneurotransmittern
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
WO2010068663A1 (en) 2008-12-10 2010-06-17 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
CN102459227B (zh) 2009-04-17 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
WO2010121036A1 (en) 2009-04-17 2010-10-21 Janssen Pharmaceutica Nv 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
TW201204717A (en) 2010-06-17 2012-02-01 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401436D0 (en) * 1994-01-26 1994-03-23 Wellcome Found Therapeutic heterocyclic compounds
JP2002510676A (ja) * 1998-04-08 2002-04-09 アメリカン・ホーム・プロダクツ・コーポレイション うつ病治療用のｎ−アリールオキシエチルアミン誘導体
CA2355342A1 (en) * 1999-01-07 2000-07-13 American Home Products Corporation Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0134598A1 *

Also Published As

Publication number Publication date
JP2003513970A (ja) 2003-04-15
CA2390531A1 (en) 2001-05-17
AU1446601A (en) 2001-06-06
MXPA02004555A (es) 2004-09-10
CN1414962A (zh) 2003-04-30
BR0015401A (pt) 2002-07-02
WO2001034598A1 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
US6245799B1 (en) [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
JP4700017B2 (ja) ピペリジン類およびピペラジン類
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
EP1546099B1 (de) 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivate als muscarinische rezeptorantagonisten
CZ20011760A3 (cs) Pyrrolidinové deriváty jako antagonisty CCR-3 receptorů
EP1228065A1 (de) [(indol-3-yl)-cycloalkyl]-3-substituierte azetidine zur behandlung von zentralnervensystem-störungen
SK50895A3 (en) 3-indolylpiperidine derivative, method of its preparation, its use for preparation of pharmaceutical composition and pharmaceutical composition containing them
EP1581522B1 (de) Flavaxat-derivate als muscarin-rezeptor antagonisten
AU617988B2 (en) Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US6066637A (en) Indolyl derivatives as serotonergic agents
AU2003214535A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
KR20050067212A (ko) 콜라게네이즈의 선택적인 억제를 위한 신규한피리미딘-4,6-디카복스아미드
US6242448B1 (en) Trisubstituted-oxazole derivatives as serotonin ligands
SK172799A3 (en) 3-benzylpiperidine derivative, process for its preparation and pharmaceutical composition containing the same
EP1073651B1 (de) Indolylderivate als serotonergische wirkstoffe
CA2074727A1 (en) Indole derivatives, their preparation and use
US5254560A (en) 2-piperidinylpyrimidine-4-carboxamide derivatives, and their use in therapeutics
US5246939A (en) 2-aminopyrimidine-4-carboxamide derivatives, their preparation and their use in therapeutics
KR100917041B1 (ko) 5-ｈｔ7 수용체에 길항작용을 갖는 신규한 화합물
EP1228064A1 (de) N-aryl-(homopiperazinyl)-cyclohexyl aminen als 5-ht überträger
US6337326B1 (en) N-aryl-(homopiperazinyl)-cyclohexyl amines
WO1999055697A1 (en) Serotonergic agents
JPH0948776A (ja) ピリミジニルピラゾール誘導体
MXPA00010456A (es) Agentes serotonergicos
WO2010133544A1 (en) Piperazine and aminopyrrolidine compounds as histamine h3 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020429

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20020429;LT PAYMENT 20020429;LV PAYMENT 20020429;MK;RO PAYMENT 20020429;SI PAYMENT 20020429

17Q First examination report despatched

Effective date: 20021205

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031216

RTI1 Title (correction)

Free format text: (INDOL-3-YL)-CYCLOALKYL -3-SUBSTITUTED AZETIDINES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS